Transcription of Under ASC 605 - Deloitte
{{id}} {{{paragraph}}}
Life Sciences Accounting and Financial Reporting Update . Interpretive Guidance on Revenue Recognition Under ASC 605. March 2017. Revenue Recognition Introduction Many transactions in the life sciences industry must be carefully analyzed for revenue recognition purposes. Revenue recognition topics that are particularly relevant to life sciences entities include the SAB Topic 131 requirements ( , sales price is fixed or determinable, collectibility is reasonably assured); the accounting for multiple elements; the ability to estimate returns; and the accounting for discounts, rebates, and incentives. Further, biotech and pharmaceutical firms may sometimes encounter complexities related to the milestone method of accounting, the proportional performance method of revenue recognition, principal-agent considerations, license fees, contingent revenue, and up-front payments.
Mar 03, 2016 · payments. Meanwhile, medical device companies may have to analyze warranties, shipping terms, consignment sales, customer financing, and the potential applicability of lease and software revenue recognition requirements. Life sciences entities also rely heavily on collaborative arrangements to leverage expertise and manage risk.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}